About Eikonoklastes
Eikonoklastes is a Healthcare company based in Columbus (United States) founded in 2019 by Zhiwei Hu and Samuel Lee. Tissue factor targeting therapeutics for cancer treatment are developed. Eikonoklastes has raised $20.76 million across 5 funding rounds from investors including Elk Capital Partners, CincyTech and JobsOhio. The company has 3 employees. Its chief executive, as recorded, is Bruce M Halpryn. Eikonoklastes offers products and services including ET-101 and SynCav1. Its focus areas include Life Sciences, Oncology, Drugs and Breast Cancer. Its competitors include Daré Bioscience, Olema Oncology and Emergent BioSolutions; 1 of its 3 listed competitors has raised funding.
Company details
Developer of tissue factor targeting therapeutics to treat cancer. The company is developing tissue factor targeting therapies that target cell surface receptors for cancers, endometriosis, and other diseases. The company has developed an L-ICON3 platform to create immune therapies engineered with a ligand conjugated to an IgG3 Fc to enable it to bind to cancer cells and treat triple-negative breast cancer. The cells activate complement activation (CDC) and antibody-dependent cellular cytotoxicity (ADCC) to kill cancer cells.
- Headquarters Columbus, United States
- Employees 3
- Founders Zhiwei Hu, Samuel Lee
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website eikonoklastes.com
- Social LinkedIn
- Total Equity Funding$20.76M (USD)
in 5 rounds
- Latest Funding Round$13.56M (USD), Series B
Jul 2025
- InvestorsElk Capital Partners
& 3 more
- Employee Count3
Products & Services of Eikonoklastes
Eikonoklastes offers a comprehensive portfolio of products and services, including ET-101 and SynCav1.
Overexpresses Caveolin-1 to protect neurons in neurodegenerative diseases.
Delivers gene copies for neuroprotection in ALS and similar conditions.
Funding Insights of Eikonoklastes
Eikonoklastes has successfully raised a total of $20.76M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $13.56 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $20.76M
- Total Rounds 5
- Last Round Series B — $13.56M
- Investors Count 4
All 5 funding rounds of Eikonoklastes with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2025 | $13.56M | Series B | – | – | – |
| Jun 2024 | $2.4M | Series B | – | – | – |
| Nov 2023 | $2M | Series A | – | – | – |
| Jan 2022 | $2.8M | Series A | – | – | – |
| Jun 2021 | Series A | – | CincyTech |
4 investors in total: 4 institutional.
Investors in Eikonoklastes
Eikonoklastes has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Elk Capital Partners, CincyTech and JobsOhio.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
CincyTech is engaged in venture capital investments for innovative startups. | cincytechusa.com | Cincinnati, USA | ||
Startup Studio building companies in the US & Europe and Angel Network for Ohio based companies | rev1ventures.com | Columbus, United States | ||
Provider of capital partners is a fundless sponsor | 2015 | elkcapitalpartners.com | Chicago, United States | |
JobsOhio is focused on economic development in Ohio. | jobsohio.com | Columbus, United States |
Investor details for Eikonoklastes
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Eikonoklastes
16 people are tracked at Eikonoklastes (6 in leadership, 9 in board & advisors, 1 in team); the tracked headcount is 3.
| Name | Role | Group |
|---|---|---|
Zhiwei Hu | Co-Founder | Leadership |
Samuel Lee | Co-Founder & President | Leadership |
Bruce M Halpryn | CEO | Leadership |
Bruce Halpryn | Co-Founder & CEO | Leadership |
Vishal Agrawal | VP, CMC | Leadership |
Samuel Lee, MD, MBA | Co-Founder, President, and Chief Business Officer | Leadership |
Tom Finn | Director | Board & advisors |
Kenneth Morand | Director | Board & advisors |
Neel Patel | Director | Board & advisors |
Meyer Frucher | Board Member | Board & advisors |
Seward Rutkove | Scientific Advisor | Board & advisors |
Michael O’Beirne | Scientific Advisor | Board & advisors |
Mark Tuszynski | Scientific Advisor | Board & advisors |
Dame Pamela Shaw | Scientific Advisor | Board & advisors |
Russell Lonser | Scientific Advisor | Board & advisors |
Brian Head | Inventor | Team |
Complete people profiles for Eikonoklastes
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Eikonoklastes
3 dated milestones of Eikonoklastes across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Eikonoklastes is founded.
- Funding First funding round.
- Funding Latest funding round, Series B, of $13.6M.
Competitors of Eikonoklastes
Eikonoklastes has 3 listed competitors in our database, 1 of them funded. They include Daré Bioscience, Olema Oncology and Emergent BioSolutions.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| darebioscience.com | 2005 | San Diego, United States | 30 | Non-hormonal pharmaceutical products for female contraceptives are developed. | ||
| olema.com | 2007 | San Francisco, United States | $139M | 74 | Drug therapeutics for breast cancer treatment are developed. | |
| emergentbiosolutions.com | 1998 | Gaithersburg, United States | 1 | Vaccines for viral infections are developed by the company. |
Detailed competitors of Eikonoklastes
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Eikonoklastes
The website of Eikonoklastes (eikonoklastes.com) receives about 1.3K visits a month and ranks #11,228,073 among all websites worldwide, #8,072 in Biotechnology and Pharmaceuticals.
- Monthly visits1.3K
- Global rank#11,228,073
among all websites
- Category rank#8,072
Health · Biotechnology and Pharmaceuticals
- Bounce rate35%
- Pages per visit1.7
- Average visit35 sec
- DevicesDesktop 16% · Mobile 84%
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Eikonoklastes (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Eikonoklastes
Complete news archive for Eikonoklastes
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eikonoklastes
Eikonoklastes was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Eikonoklastes is headquartered in Columbus, United States. It is registered at Columbus, Ohio, United States.
Bruce M Halpryn is the CEO of Eikonoklastes, as recorded in our data.
Eikonoklastes is a funded company, having raised a total of $20.76M across 5 funding rounds to date.
Eikonoklastes has 3 employees.
Developer of tissue factor targeting therapeutics to treat cancer. The company is developing tissue factor targeting therapies that target cell surface receptors for cancers, endometriosis, and other diseases. The company has developed an L-ICON3 platform to create immune therapies engineered with a ligand conjugated to an IgG3 Fc to enable it to bind to cancer cells and treat triple-negative breast cancer. The cells activate complement activation (CDC) and antibody-dependent cellular cytotoxicity (ADCC) to kill cancer cells.
Eikonoklastes's top competitors include Daré Bioscience, Olema Oncology and Emergent BioSolutions.
Eikonoklastes offers ET-101 and SynCav1.
Eikonoklastes has 4 investors. Key investors include Elk Capital Partners, CincyTech, JobsOhio, and Rev1 Ventures.